Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

625 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications.
Vitale A, Farinati F, Finotti M, Di Renzo C, Brancaccio G, Piscaglia F, Cabibbo G, Caturelli E, Missale G, Marra F, Sacco R, Giannini EG, Trevisani F, Cillo U, Associazione Italiana Per Lo Studio Del Fegato Aisf Hcc Special Interest Group, Italian Liver Cancer Ita Li Ca Study Group. Vitale A, et al. Among authors: marra f. Cancers (Basel). 2021 Apr 2;13(7):1673. doi: 10.3390/cancers13071673. Cancers (Basel). 2021. PMID: 33918125 Free PMC article. Review.
The evolutionary scenario of hepatocellular carcinoma in Italy: an update.
Bucci L, Garuti F, Lenzi B, Pecorelli A, Farinati F, Giannini EG, Granito A, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cammà C, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Bucci L, et al. Among authors: marra f. Liver Int. 2017 Feb;37(2):259-270. doi: 10.1111/liv.13204. Epub 2016 Aug 17. Liver Int. 2017. PMID: 27427866
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.
Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, Tovoli F, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Boccaccio V, Craxì A, Bruno S, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) Group. Petta S, et al. Among authors: marra f. Aliment Pharmacol Ther. 2017 Jan;45(1):160-168. doi: 10.1111/apt.13821. Epub 2016 Oct 28. Aliment Pharmacol Ther. 2017. PMID: 27790734 Free article.
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma.
Cabibbo G, Petta S, Barbàra M, Missale G, Virdone R, Caturelli E, Piscaglia F, Morisco F, Colecchia A, Farinati F, Giannini E, Trevisani F, Craxì A, Colombo M, Cammà C; ITA.LI.CA study group. Cabibbo G, et al. Liver Int. 2017 Aug;37(8):1157-1166. doi: 10.1111/liv.13357. Epub 2017 Feb 1. Liver Int. 2017. PMID: 28061016
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
Cabibbo G, Petta S, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, Negrini G, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Mega A, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Craxì A, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) group. Cabibbo G, et al. Among authors: marra f. J Hepatol. 2017 Jul;67(1):65-71. doi: 10.1016/j.jhep.2017.01.033. Epub 2017 Feb 10. J Hepatol. 2017. PMID: 28192185
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.
Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Giannini EG, et al. Among authors: marra f. Hepatology. 2018 May;67(5):1784-1796. doi: 10.1002/hep.29668. Epub 2018 Apr 6. Hepatology. 2018. PMID: 29159910 Free article.
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.
Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A, Granito A, Tovoli F, De Lorenzo S, Inghilesi AL, Foschi FG, Bernardi M, Marra F, Sacco R, Di Costanzo GG. Trevisani F, et al. Among authors: marra f. J Cancer Res Clin Oncol. 2018 Feb;144(2):403-414. doi: 10.1007/s00432-017-2556-6. Epub 2017 Dec 16. J Cancer Res Clin Oncol. 2018. PMID: 29249005 Free article.
Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group.
Vitale A, Lai Q, Farinati F, Bucci L, Giannini EG, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Pawlik TM; Italian Liver Cancer (ITA.LI.CA) group. Vitale A, et al. Among authors: marra f. J Gastrointest Surg. 2018 May;22(5):859-871. doi: 10.1007/s11605-018-3688-y. Epub 2018 Jan 19. J Gastrointest Surg. 2018. PMID: 29352441
625 results